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Abstract
Pseudomonas aeruginosa infection is a hallmark of lung disease in cystic fibrosis. Acute infection 
with P. aeruginosa profoundly inhibits alveolar macrophage clearance of apoptotic cells 
(efferocytosis) via direct effect of virulence factors. During chronic infection, P. aeruginosa 
evades host defense by decreased virulence, which includes the production or, in the case of 
mucoidy, overproduction of alginate. The impact of alginate on innate immunity, in particular on 
macrophage clearance of apoptotic cells is not known.
We hypothesized that P. aeruginosa strains that exhibit reduced virulence impair macrophage 
clearance of apoptotic cells and we investigated if the polysaccharide alginate produced by mucoid 
P. aeruginosa is sufficient to inhibit alveolar macrophage efferocytosis.
Rat alveolar or human peripheral blood monocyte (THP-1)-derived macrophages cell lines were 
exposed in vitro to exogenous alginate or to wild type or alginate-overproducing mucoid P. 
aeruginosa prior to challenge with apoptotic human Jurkat T-lymphocytes. The importance of 
LPS contamination and that of structural integrity of alginate polymers was tested using alginate 
of different purities and alginate lyase, respectively.
Alginate inhibited alveolar macrophage efferocytosis in a dose- and time-dependent manner. This 
effect was augmented but not exclusively attributed to lipopolysaccharide (LPS) present in 
alginates. Alginate-producing P. aeruginosa inhibited macrophage efferocytosis by more than 
50%. Although alginate lyase did not significantly restore efferocytosis in the presence of 
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exogenous alginate, it had a marked beneficial effect on efferocytosis of alveolar macrophages 
exposed to mucoid P. aeruginosa.
Despite decreased virulence, mucoid P. aeruginosa may contribute to ongoing airway 
inflammation through significant inhibition of alveolar clearance of apoptotic cells and debris. The 
mechanism by which mucoid bacteria inhibit efferocytosis may involve alginate production and 
synergy with LPS, suggesting that alginate lyase may be an attractive therapeutic approach to 
airway inflammation in cystic fibrosis and other chronic obstructive pulmonary diseases 
characterized by P. aeruginosa colonization.
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Introduction
Cystic fibrosis (CF) is the most common autosomal recessive disorder with an estimated 
incidence of 1 in 3,000 Caucasians [1]. The majority of individuals with CF have positive 
sputum cultures for Pseudomonas aeruginosa. Infection with P. aeruginosa is associated 
with significant morbidity and mortality [2, 3]. Neutrophils (PMN) constitute an initial line 
of defense against P. aeruginosa infection via phagocytosis of bacteria, which is followed 
by neutrophil apoptosis. In turn, apoptotic cell clearance (efferocytosis) from the airways by 
alveolar macrophages (AM) is an essential step in the resolution of inflammation [4, 5].
It has been established that the acute infectious (planktonic) P. aeruginosa increases PMN 
apoptosis but decreases their clearance by AM by mechanisms involving pyocyanin and 
Type III Secretion System (T3SS) production, classical virulence factors of this bacteria [6, 
7]. This mechanism may be partly responsible for chronic PMN infiltration of CF airways, 
increased mucous viscosity, and perpetuation of airway inflammation. However, with the 
transition to chronicity, microbes accumulate mutations rendering CF airways frequently 
colonized by P. aeruginosa strains with lower virulence [8-10]. These strains associated 
with chronic airway infections produce more biofilms and down-regulate T3SS and 
pyocyanin production, attempting to evade host immunity [11]. Despite this decrease in 
expression of classical virulence factors, mucoid P. aeruginosa, an alginate overproducing 
mutant [12] often found in CF sputum cultures, is associated with higher morbidity and 
mortality in persons with CF [13]. The alginate-containing biofilm produced by the mucoid 
strain has been shown to impair antibiotic penetration and to inhibit phagocytosis of 
bacteria, whereas treatment with alginate lyase improves antibiotic responses and sputum 
viscosity [14-16]. However, bacterial and apoptotic cell phagocytosis do not share similar 
mechanisms. The effects of alginate on AM efferocytosis is unknown and could play an 
essential role in airway inflammation and therefore the morbidity of chronic P. aeruginosa 
infection. Accordingly, restoration of inflammatory clearance by means of mitigating 
alginate production or breaking down its polymers with alginate lyase might provide the 
rationale for potential therapeutic interventions, especially in the setting of increased 
antibiotic resistance.
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We hypothesize that alginate produced by less virulent, mucoid P. aeruginosa will decrease 
AM efferocytosis and that alginate lyase treatment will improve AM engulfment of 
apoptotic cells in the presence of mucoid bacteria.
Materials and Methods
Reagents
All reagents were from Sigma-Aldrich (St. Louis, MO), unless otherwise specified. LPS, 
from E. coli strain O111:B4 was from Thermo Scientific (Asheville, NC).
Cells
Rat alveolar macrophages (AM) cell line NR8383 (ATCC, Manassas, VA) was maintained 
in Ham’s F12K medium (ATCC) containing L-glutamine (2 mM), sodium bicarbonate (1.5 
g/L), and heat-inactivated fetal bovine serum (FBS, 15%). Select experiments (as noted) 
were performed with monocyte derived macrophages from THP-1 (ATCC) differentiated 
with phorbol 12-myristate 13-acetate (PMA; 5 nM, 48h). Human acute T cell leukemia cell 
line Jurkat (ATCC) was maintained in RPMI-1640 supplemented with heat-inactivated FBS 
(10%), penicillin (100 U/ml), and streptomycin (0.1 mg/ml). All cells were maintained in an 
incubator at 37°C, 5% CO2.
Treatments
Cells were treated with sodium alginate (Spectrum Chemical, New Brunswick, NJ) at 0.2 
mg/l, 0.5 mg/ml, 1.0 mg/ml, or 2.5 mg/ml or its vehicle (sterile water) for 0, 4, or 24 h in 
F12K media with 2% FBS at 37°C, 5% CO2. These alginate concentrations are within 
ranges used in studies investigating alginate interactions with P. aeruginosa [17], as well as 
similar to alginate levels produced by certain mucoid P. aeruginosa strains [18, 19]. After 
treatment, AM were either immediately used, or were first rinsed in PBS and then used, or 
were rinsed and then recovered for 24 h in full culture media and then used in efferocytosis 
experiments, as indicated. Alginate preparations are often contaminated with LPS due to 
processing conditions. Thus, to investigate the role of LPS contamination, alginate was 
assayed using a Limulus Amebocyte Lysate (LAL) based kit (Thermo Scientific) and 
compared to other alginate preparations (Pronova-Nova Matrix, Ewing, NJ), which were 
ultra-purified (LPS-free), as noted.
Efferocytosis
Apoptotic targets were obtained from Jurkat cells labeled with Cell Tracker Orange 
(Invitrogen, Grand Island, NY; 0.5 mM) and exposed to UV radiation (30,000 μJ/cm2) using 
a HL-2000 HybriLinker, followed by incubation for 3.5 h at 37°C, 5% CO2 in serum-free 
media. Apoptotic Jurkat cells were co-cultured (1 h at 37°C) with AM in a 5:1 ratio. 
Afterwards, cells were collected and extracellular fluorescence (of membrane-bound but 
non-engulfed apoptotic cells or bodies) was quenched with Trypan Blue (Sigma; 500μl; 
0.04% in PBS) [20]. Cells were then fixed with 1% paraformaldehyde. Efferocytosis was 
evaluated by flow cytometry using Cytomics FC500 cytofluorimeter with CXP software 
(Beckman Coulter, Fullerton, CA), as described (Fig. 1A) [20].
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The strains of P. aeruginosa used were PA14 (a highly virulent human clinical isolate) [21], 
PA01 (the standard laboratory reference strain) [22], and FRD1 (a mucoid strain isolated 
from a CF patient) [23]. The following mutants were used: isogenic deletion mutant for the 
genes phzM and exsA in PA14 (PAKO), which lacks pyocyanin and T3SS, an algD mutant 
in PA01 to eliminate alginate production [24, 25]. Isogenic deletions in phzM and exsA were 
created using an allelic replacement technique, as previously described [24]. For phzM 
mutation, we used the primers PhzMLfor (5′ TCG ACT GAG CCT TTC GTT TTA TTT 
GAT GCC TGG CAG TTC CGA TCC TCG GTC TCG AAG ATC 3′), PhzMLrev (5′ CAG 
CCG TTG AGA GTT CCG GTC TCT CGT TAC ACA TTT CCG T 3′), PhzMRfor (5′ 
ACG GAA ATG TGT AAC GAG AGA CCG GAA CTC TCA ACG GCT G 3′), and 
PhzMRrev (5′ GGA ATT GTG AGC GGA TAA CAA TTT CAC ACA GGA AAC AGC 
TAG TGG GAA ATC GAC CTG TTC 3′). Deletions were confirmed by PCR using primers 
PhzMfor (5′ GTT GTT TCC GCA ACG AGA TC 3′) and PhzMrev (5′ GCA ACG CGC 
TCA ACC AAC TG 3′). Deletion of exsA was described previously [25]. The algD mutant 
was kindly donated by Dr. George O’Toole, Geisel School of Medicine at Dartmouth. 
Bacteria were grown overnight in liquid LB media and then working suspensions were 
prepared to an OD600 of 0.6, as measured by spectrometry. These bacterial suspensions and 
apoptotic cells were co-cultured with macrophages for 1 h. Where indicated, alginate lyase 
was added to bacterial suspensions alone for 4 h before efferocytosis experiments.
Alginate lyase activity
Alginate lyase was obtained from Sphingobacterium multivorum (Sigma-Aldrich), and has 
specificity for cleaving manuronic acid bonds. The reaction was initiated by adding alginate 
lyase (in PBS, pH 7.4) to alginate (1:30 vol:vol). The enzyme activity (4h at 37 °C) was 
measured with a SpectraMax M2 plate reader (Molecular Devices Inc., Sunnyvale, CA) at 
235 nm.
Cellular toxicity was determined using an in vitro MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide) assay, according to the manufacturer’s (Sigma) protocol. The 
absorbance of formazan was measured at 570 nm with a SpectraMax M2 plate reader.
Statistical methods
Differences among groups were assessed using either t-test for two groups or ANOVA for 3 
or more groups with post-hoc Tukey’s testing for significant differences between selected 
groups. Statistical difference was considered significant when p<0.05. Analyses were 
performed using Prism Software (GraphPad Software, Inc. La Jolla, CA).
Results
Effect of alginate on AM efferocytosis
We first determined if alginate, a complex copolymer present in the biofilm formed by P. 
aeruginosa during chronic infections, is sufficient to impair AM efferocytosis. We exposed 
rat AM (NR8383 cell line) to exogenous sodium alginate suspensions of varying 
concentrations (Fig. 1B) and for varying amount of time (Fig. 1C), followed by AM co-
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culture with apoptotic targets. Alginate inhibited efferocytosis of apoptotic targets 
(fluorescently-labeled UV-irradiated Jurkat T-cells) in a dose- and time-dependent fashion, 
as measured by flow cytometry. The highest dose of alginate tested (2.5 mg/ml) exerted an 
inhibitory effect on AM efferocytosis after as early as 5 minutes of treatment, and was most 
profound after 24 h of incubation.
To determine the persistence of efferocytosis impairment following treatment with sodium 
alginate, rat AM efferocytosis was investigated following the removal of alginate. After 
alginate treatment, cells were either rinsed and immediately co-cultured with apoptotic 
targets, or were rinsed and allowed to recover in fresh media for 24 h prior to co-culture 
with apoptotic targets (Fig. 1D). The immediate removal of alginate from the co-culture did 
not significantly change the inhibitory impact on AM efferocytosis. Interestingly, cells that 
were allowed to recover overnight exhibited only partial (20%) restoration of their 
efferocytosis potential compared with cells from which alginate was not rinsed, and only a 
non-significant (9%, p=0.4) recovery in efferocytosis compared to cells that were tested 
immediately after alginate was rinsed. Given the persistence of the effect of alginate on 
efferocytosis, to rule out a nonspecific toxic effect, we tested if alginate (2.5 mg/ml) altered 
macrophage viability, as measured by MTT assay (Fig. 1E). Macrophages exposed to 
alginate did not show decreased metabolic toxicity, suggesting that alginate is a potent 
inhibitor of alveolar macrophage efferocytosis and that its effect is not merely due to the 
physical presence of alginate in co-cultures or due to a non-specific irreversible toxic effect 
on AM.
Effects of LPS on AM efferocytosis
Since purified alginate may be contaminated with varying levels of lipopolysaccharide 
(LPS) [26], we investigated the levels and potential contribution of LPS contamination of 
alginate on efferocytosis. The alginate used in the experiments above was tested using the 
limulus amebocyte assay and found to contain 100 EU LPS/g of alginate, which is 
considered a low level of contamination [26]. We then compared the effect of this alginate 
(1 EU LPS/ml alginate) with that of highly purified alginates (0.3 and 0.4 EU LPS/ml 
alginate, respectively) on efferocytosis. We noted that alginate containing lower levels of 
LPS had less inhibitory effect on efferocytosis (Fig. 2), suggesting a contributory effect of 
LPS on alginate-induced AM dysfunction. However, comparable exposures (4h) to LPS 
alone without alginate, in concentrations even higher than those found in alginate did not 
inhibit AM efferocytosis (Fig. 2). These results suggest a cooperative effect of LPS and 
alginate on macrophage engulfment of apoptotic cells.
Effects of P. aeruginosa on AM efferocytosis
We investigated if alginate-producing (mucoid) strains of P. aeruginosa, typically present in 
the biofilm of CF chronic airway infection, inhibit efferocytosis. We studied the effect of a 
mutant P. aeruginosa lacking the pyocyanin and T3SS toxins (PAKO) relative to the wild-
type (PA14) P. aeruginosa strain, which is known to inhibit efferocytosis via production of 
toxins such as pyocyanin [7]. The toxin-deficient strain significantly inhibited efferocytosis 
by more than 50% (Fig. 3). This inhibitory effect was less potent compared to wild type 
bacteria which depressed efferocytosis by 70%, but it was remarkably similar to the effect of 
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alginate alone. As a comparison, we also tested a CF-adapted, mucoid strain (FRD1). 
Importantly, this mucoid strain also inhibited efferocytosis by more than 50% (Fig. 3).
Impact of alginate lyase (AL) treatment on efferocytosis
We tested if the breakdown of high-molecular weight alginate polymers with AL will 
prevent its inhibitory effect on efferocytosis. After testing the activity of purified AL at 
neutral pH (Fig. 4A), we incubated AL with exogenous alginate prior to exposure of AM. 
Whereas AL treatment did not affect the inhibitory effect of alginate on AM efferocytosis 
(Fig. 4B), it significantly attenuated the effect of mucoid, alginate producing (FRD1) P. 
aeruginosa on efferocytosis (Fig. 4C). However, AL had no impact on efferocytosis 
inhibition in response to wild type P. aeruginosa or an alginate non-producer mutant strain 
(data not shown). These data suggest that alginate is in large part responsible for the 
efferocytosis inhibitory effect of mucoid P. aeruginosa.
Discussion
Whereas the pathogenic effects of P. aeruginosa during acute infections are attributed in 
large part to toxin production, the production of virulent toxins is markedly decreased during 
chronic bacterial persistence in biofilm [27, 28]. Whereas the low virulence of P. aeruginosa 
in biofilm infections accounts for decreased anti-bacterial host responses, it is becoming 
increasingly evident that biofilm-state P. aeruginosa continues to exert pathogenic effects 
on the airways. The main finding of this report is that even P. aeruginosa with low virulence 
inhibits the clearance of apoptotic cells by macrophages, a critical innate host defense 
mechanism. We further report that this pathogenic effect may be due to a synergistic effect 
of alginate and LPS.
Similar to findings of Bianchi et al., our data indicate that wild type, pyocyanin-producing 
virulent P. aeruginosa has profound inhibitory effect on efferocytosis [7]. In addition, we 
show that even bacteria that lack these virulence factors can inhibit efferocytosis, albeit to a 
lesser degree. The dose-dependent effect of alginate on efferocytosis implicates this 
complex copolymer as one of the mediators by which mucoid P. aeruginosa inhibits 
macrophage engulfment of apoptotic cells. Of the three exopolymers secreted by mucoid P. 
aeruginosa Pel, Psl, and alginate, only the latter is found in bacteria adapted to the CF lung 
[29]. Alginate has been involved in other effects of mucoid P. aeruginosa on the innate 
immunity, such as decreased phagocytosis of bacteria by PMN, in addition to decreasing 
local antibiotic penetration, or, at higher concentrations, modulating the T3SS of the bacteria 
[17]. Secreted in abundance by mucoid P. aeruginosa, alginate is an unbranched 
polysaccharide composed of monomers of L-guluronic acid and D-mannuronic acid [30]. 
While pure alginate does not contain LPS, the steps necessary to purify alginate from 
various sources are associated with varied degrees of contamination of alginate with LPS. 
For example, alginate purified from cultured mucoid bacteria is typically contaminated with 
approximately 900 EU/ml LPS [31]. The commercial alginate preparation purified from 
algae used in our study contained 4-fold less LPS than alginate typically purified from 
bacteria. Although bacterial LPS alone at similar concentrations did not inhibit macrophage 
efferocytosis, we demonstrated a cooperative effect of LPS with alginate to inhibit 
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efferocytosis. Whether this phenomenon could be explained by common signaling pathways 
engaged by alginate and LPS, such as TLR4 receptor activation, will need experimental 
confirmation in future investigations. One cannot exclude the possibility that other 
contaminants in the alginate extract, or other immunogenic components of the biofilm in 
addition to alginate, may impact efferocytosis [32]. However, our results showing the effect 
of alginate-producing P. aeruginosa, which was diminished by AL, suggest alginate-specific 
inhibition of efferocytosis. Although not directly compared in our model, our results also 
suggest that both bacteria producing alginate and algae alginate have inhibitory effects on 
efferocytosis, despite structural dissimilarities of the two exopolymers. The mechanism by 
which alginate impairs efferocytosis may include alternation of expression or accessibility of 
efferocytosis-required receptors at the plasma membrane. Such a candidate could be 
ABCA1, one of the twelve members of the ABC transporter system that plays an important 
role in efferocytosis [33], since alginate molecules interact via the ABC system [34] and 
ABCA1 has been shown to be downregulated by LPS [35].
It is interesting that the enzymatic breakdown of the copolymer by incubation with AL did 
not rescue efferocytosis impaired by marine alginate, whereas the enzyme was effective in 
rescuing efferocytosis inhibited by alginate-overproducing bacteria. It is possible that the 
effectiveness of the enzyme may be related to reaction conditions in vitro or to substrate 
accessibility, given the variability in monomer type predominance and acetylation of 
different alginates [36]. In particular, the AL used in our experiments has specificity for 
manuronic acid. The fact that guluronate is more prevalent in algal alginate and 
mannuronate is more abundant in Pseudomonas alginate may explain why AL was more 
effective in cleaving bacterial alginate. Although AL may be inhibited by acetylation [37] 
and bacterial alginate is heavily acetylated, treatment of alginate overproducing P. 
aeruginosa strain FRD1 with AL led to significant increases (and partial recovery) in 
efferocytosis and support the notion that bacterial alginate, like algal alginate, contributes to 
the detrimental effect of mucoid P. aeruginosa on this innate immune function.
The approach used in our studies relied on ex vivo observations of macrophage function, due 
to the difficulty to establish chronic mucoid P. aeruginosa airway infection or colonization 
in animals [38]. Nevertheless, these results may be relevant to human lung diseases 
characterized by airway colonization and chronic biofilm infection with P. aeruginosa, such 
as CF, COPD, and non-CF bronchiectasis. Chronic airway infection with P. aeruginosa is 
known to decrease lung function and increased mortality in CF and is characterized by 
production of a biofilm containing the polysaccharide alginate and by decreased microbial 
virulence, in attempt to evade host immunity. Indeed, the biofilm matrix, composed of 
extracellular polysaccharides such as alginate, Pel, and Psl [29] along with DNA, protein, 
and other host components, protect the constituent bacteria from immune attack and from 
antibiotic treatment [9]. Despite the decreased virulence, mucoid P. aeruginosa is still 
associated with decline in lung function. We have shown that alginate decreases the removal 
of dead cells by macrophages, which may cause prolonged airway inflammation and lung 
dysfunction. Since mucoid biofilm infections are characterized by marked secretion of 
alginate [39, 40], our data implicate the mucoid P. aeruginosa in airway inflammation, 
associated with alginate inhibition of alveolar macrophage efferocytosis. The impairment of 
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lung macrophage efferocytosis contributes to airway inflammation through mechanisms that 
include release of pro-inflammatory mediators from non-engulfed apoptotic cells (via 
secondary necrosis), increased mucus viscosity from spilled DNA, and loss of anti-
inflammatory phenotype of alveolar macrophages associated with apoptotic cell engulfment. 
Several studies suggest that airway inflammation further propagates bacterial biofilm 
persistence. The released intracellular proteins and nucleic acids, which increase airway 
mucus viscosity, enhance the bacterial biofilm matrix that surrounds and protects bacteria 
[41]. Biofilm polysaccharides themselves exert a positive feedback on further biofilm 
synthesis [42]. In addition, persistently activated immune cells, which may include 
macrophages with impaired efferocytosis, exert oxidative stress which promotes P. 
aeruginosa mutations (mucA) that stimulate alginate overexpression [9, 43]. These 
dysregulated host-microbe interactions support that alginate lyase or other methods to 
mitigate alginate accumulation in the airway may decrease airway inflammation and biofilm 
formation in chronic P. aeruginosa infection in CF and other bronchiectatic patients.
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Fig. 1. Effect of sodium alginate on efferocytosis
(A) Schematic of efferocytosis flow-cytometry method. Macrophage population was gated 
on FSC/SSC (gate B) and set for negative fluorescence (autofluorescence) on FSC/FL2 
panel (gate AJ). When assessing the engulfment, the macrophages which engulfed apoptotic 
targets can be seen as a population of larger and more complex events in panel FSC/SSC 
(black) which were then evaluated (and measured as % cells which engulfed fluorescent 
targets) in panel FSC/FL2. The quenching with trypan blue discriminated engulfed from 
potentially attached apoptotic targets. (B-D) Efferocytosis of apoptotic Jurkat cells by rat 
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alveolar macrophages (NR8383 cell line) in the presence of alginate at the indicated 
concentrations (B, 24 h) and time points (C, 2.5 mg/ml). Efferocytosis was expressed as 
relative phagocytic index (% of vehicle control; Mean + SEM; n=3; (Mean+SEM of control 
47.35+2.49); B: ANOVA, p ≤ .0001; Tukey’s post-hoc * p ≤ 0.0001 and # p ≤ 0.01); (C) 
(Mean+SEM of control 35.55+2.55); ANOVA, p ≤ .0001; Tukey’s post-hoc * p ≤ 0.0001. 
(D) Efferocytosis index of rat alveolar macrophages (NR8383) following exposure to 
alginate (2.5 mg/ml; 4 h). Engulfment was assessed in co-cultures in the presence of alginate 
(present), immediately following removal of alginate (rinsed), or 24h following removal of 
alginate (rinsed & recovered). (Mean + SEM of control 29.9+3.24); n=3; ANOVA, p ≤ .
0001; Tukey’s post-hoc # p ≤<0.0001, $ p<0.01,* p< 0.05. (E-F) Metabolic activity 
measured by MTT assay in macrophages in the following conditions: untreated, vehicle 
treated (water) and alginate (2.5 mg/ml) treated for 4 h and 24h, respectively (Mean + SEM, 
n=3).
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Fig. 2. Impact of lipopolysaccharide (LPS) in alginate on efferocytosis
Efferocytosis index of alveolar macrophages (NR8383) following exposure to alginate (2.5 
mg/ml; 4h; 0.25 EU LPS /ml of media) compared to alginate preparations with low LPS 
contamination (final concentrations of LPS in media as indicated), or to LPS alone (1 EU/
ml). Mean + SEM; (Mean + SEM of control 53.17+7.31); n=3; ANOVA, p < 0.0001; 
Tukey’s post-hoc * p <0.0001 # p<0.005 and $ p<0.01.
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Fig. 3. Efferocytosis of alveolar macrophages exposed to P. aeruginosa strains
Efferocytosis index of rat alveolar macrophages (NR8383) during exposure to the following 
strains of P. aeruginosa: wild type (WT; non-mucoid; PA14), mutated (virulence-attenuated 
PAKO), or mucoid (alginate overproducer; FRD1). The ratio of bacteria: macrophages; 
apoptotic cells during co-culture was 1:5:5. Mean + SEM; (Mean + SEM of control 
50.13+4.8;) n=3; ANOVA p < 0.0001; Tukey’s post-hoc *p <0.0001; # p<0.01.
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Fig. 4. Effect of alginate lyase (AL) on efferocytosis inhibition by alginate and alginate-producing 
P. aeruginosa
(A) AL activity (mU /min; pH 7.4) measured during incubation of purified AL (1U/ml) with 
its substrate alginate (Alg, 2.5 mg/ml), compared to controls such as vehicle (Veh), alginate 
alone, or AL in the absence of substrate. Mean + SEM; n=3. (B) Effect of pre-incubation of 
AL with alginate (at the indicated concentrations; 1:30 v:v ratio AL:alginate; 45 min.) on 
efferocytosis of alveolar macrophages (NR8383 cells) exposed to alginate (2.5 mg/ml; 4h). 
Mean + SEM; (Mean + SEM of control 40.62+4.3); n=6; t-test *p< 0.05. (C) Effect of pre-
incubation of AL (1U/ml; 4 h) with mucoid P. aeruginosa (alginate overproducer; FRD1) on 
efferocytosis of human peripheral blood monocyte (THP-1)-derived macrophages. The ratio 
of bacteria: macrophages:apoptotic cells was 2.5:1:5. Mean + SEM; (Mean + SEM of 
control 48.19+5.03); n=3; ANOVA p < 0.0001; Tukey’s post-hoc *p <0.01, #p< 0.05.
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